Postmenopausal Canarian women receiving oral glucocorticoids have an increased prevalence of vertebral fractures and low values of bone mineral density measured by quantitative computer tomography and dual X-ray absorptiometry, without significant changes in parathyroid hormone

European Journal of Internal Medicine

Volumn 19, Issue 1, 2008, Pages 51-56

  Sosa, M ^a   Jodar E ^b   Saavedra, P ^c   Navarro, M C ^c   Gomez de Tejada M J ^d   Martin A ^a   Pena P ^a   Gomez J ^a  

^a HOSPITAL UNIVERSITARIO INSULAR DE GRAN CANARIA   (Spain)

^b HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^c UNIVERSITY OF LAS PALMAS DE GRAN CANARIA   (Spain)

^d UNIVERSITY OF SEVILLE   (Spain)

Author keywords

Bone mineral density; Bone turnover; Canary Island; DXA; Fractures; Glucocorticoids; Osteocalcin; Osteoporosis; Postmenopausal women; PTH; QCT; TRAP

Indexed keywords

BIOCHEMICAL MARKER; GLUCOCORTICOID; OSTEOCALCIN; PARATHYROID HORMONE; PREDNISONE;

ADULT; ARTICLE; BONE DENSITY; BONE REMODELING; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; CORRELATION ANALYSIS; DOSE RESPONSE; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; FEMUR NECK; HIP FRACTURE; HUMAN; LUMBAR SPINE; MAJOR CLINICAL STUDY; OBSERVATIONAL STUDY; OSTEOPOROSIS; PHYSICAL EXAMINATION; POSTMENOPAUSE; PREVALENCE; QUESTIONNAIRE; RISK ASSESSMENT; SIDE EFFECT; SPINE; STATISTICAL SIGNIFICANCE; TELOMERIC REPEAT AMPLIFICATION PROTOCOL; TRABECULAR BONE; URINALYSIS; VERTEBRA FRACTURE;

ABSORPTIOMETRY, PHOTON; AGED; BONE DENSITY; CROSS-SECTIONAL STUDIES; FEMALE; GLUCOCORTICOIDS; HUMANS; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; PARATHYROID HORMONE; PREDNISONE; SPAIN; SPINAL FRACTURES; TOMOGRAPHY, X-RAY COMPUTED;

EID: 38349174168     PISSN: 09536205     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejim.2007.08.005     Document Type: Article

References (30)

1. Cummings S.R., and Melton III L.J. Epidemiology and outcomes of osteoporotic fractures. Lancet 359 (2002) 1761-1767
2. Cushing H. The basophilic adenomas of pituitary body and their clinical manifestations (pituitary basophilism). Johns Hopkins Hosp Bull 1 (1932) 137-192
3. Khosla S., Lufkin E.G., Hodgson S.F., Fitzpatrick L.A., and Melton L.J. Epidemiology and clinical features of osteoporosis in young individuals. Bone 15 (1994) 551-555
4. American College of Rheumatology Ad Hoc Committee on Glucocorticoid-Induced Osteoporosis. Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Rheum 44 (2001) 1496-1503
5. Eastell R., Reid D.M., Compston J., Cooper C., Fogelman I., Francis R.M., et al. A UK consensus group on management of glucocorticoid-induced osteoporosis: an update. J Intern Med 244 (1998) 271-292
6. Geusens P.P., de Nijs R.N.J., Lems W.F., Laan R.F.J.M., Struijs A., Van Staa T.P., et al. Prevention of glucocorticoid osteoporosis: a consensus document of the Dutch Society of Rheumatology. Ann Rheum Dis 63 (2004) 264-265
7. Homik J.E., Cranney A., Shea B., Tugwell P., Wells G., and Adachi J. A metaanalysis on the use of bisphosphonates in corticosteroid induced osteoporosis. J Rheumatol 26 (1999) 1148-1157
8. Kanis J.A., Glüer C.C., for the Committee of Scientific Advisors, and International Osteoporosis Foundation. An update on the diagnosis and assessment of osteoporosis with densitometry. Osteoporos Int 11 (2000) 192-202
9. Cann C.E. Quantitative CT for determination of bone mineral density: a review. Radiology 166 (1988) 509-522
10. Rehman Q., Lang T., Modin G., and Lane N.E. Quantitative computed tomography of the lumbar spine, not dual X-ray absorptiometry, is an independent predictor of prevalent vertebral fractures in postmenopausal women with osteopenia receiving long-term glucocorticoid and hormone-replacement therapy. Arthritis Rheum 46 (2002) 1292-1297
11. Rubin M.R., and Bilezikian J.P. The role of parathyroid hormone in the pathogenesis of glucocorticoid-induced osteoporosis. A re-examination of the evidence. J Clin Endocrinol Metab 87 (2002) 4033-4041
12. Lukert B.P. Glucocorticoid-induced osteoporosis. In: Favus M. (Ed). Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism. Fifth Edition (2003), ASBMR, Washington 364-370
13. Van Staa T.P. The pathogenesis, epidemiology and management of glucocorticoid-induced osteoporosis. Calcif Tissue Int 79 (2006) 129-137
14. O'Neill T.W., Cooper C., Cannata J.B., Díaz López J.B., Hoszowski K., Johnell O., et al., on behalf the European Vertebral Osteoporosis Study (EVOS). Reproducibility of a questionnaire on risk factors for osteoporosis in a multicentre prevalence survey: the European Vertebral Osteoporosis Study. Int J Epidemiol 23 (1994) 559-565
15. Genant H.K., Wu C.Y., van Kujic C., and Nevitt M.C. Vertebral fracture assessment using a semiquantitative technique. J Bone Miner Res 8 (1993) 1137-1148
16. Sosa M., Hernández D., Estévez S., Limiñana J.M., Saavedra P., and Láinez P. The range of bone mineral density in healthy Canarian women by dual X-ray absorptiometry radiograghy and quantitative computer tomography. J Clin Densitom 1 (1998) 385-393
17. Cann C.E., and Genant H.K. Precise measurement of the vertebral mineral content using computed tomography. J Comput Assist Tomogr 4 (1980) 493-500
18. Genant H.K., Steiger P., Block J.E., Glueer C.C., Ettinger B., and Harris S.T. Quantitative computed tomography: update 1987. Calcif Tissue Int 41 (1987) 179-186
19. Pacifici R., Rupich R., Griffin M., Chines A., Susman N., and Avioli L.V. Dual energy radiography versus quantitative computer tomography for the diagnosis of osteoporosis. J Clin Endocrinol Metab 70 (1990) 705-710
20. Adachi J., Bensen W., and Hodsman A.B. Corticosteroid-induced osteoporosis. Semin Arthritis Rheum 22 (1993) 375-384
21. Saag K.G., Emkey R., Schnitzer T.J., Brown J.P., Hawkins F., Goemaere S., et al. Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. N Engl J Med 339 (1998) 292-299
22. Cohen S., Levy R.M., Keller M., Boling E., Emkey R.D., and Greenwald M. Risedronate therapy prevents corticosteroid-induced bone loss: a twelve-month, multicenter, randomized, double-bind, placebo-controlled, parallel-group study. Arthritis Rheum 42 (1999) 2309-2318
23. Van Staa T.P., Van Staa R.F., Barton I.P., Cohen S., Reid D.M., and Cooper C. Bone density threshold and other predictors of vertebral fracture in patients receiving oral glucocorticoid therapy. Arthritis Rheum 48 (2003) 3224-3229
24. Ross P.D., Davis J., Epstein R., and Wasnick R. Pre-existing fractures and bone mass predict vertebral fracture incidence in women. Ann Intern Med 114 (1991) 919-923
25. Angeli A., Gugliemi G., Dovio A., Capelli G., de Feo D., Giannini S., et al. High prevalence of asymptomatic vertebral fractures in post-menopausal women receiving chronic glucocorticoid therapy: a cross-sectional outpatient study. Bone 39 (2006) 253-259
26. Steinbuch M., Youket T.E., and Cohen S. Oral glucocorticoid use is associated with an increased risk of fracture. Osteoporos Int 15 (2004) 323-328
27. De Vries F., Bracke M., Leufkens H.G., Lammers J.W., Cooper C., and Van Staa T.P. Fracture risk with intermittent high-dose oral glucocorticoid therapy. Arthritis Rheum 56 (2007) 208-214
28. Cooper C., O'Neill T., Silman A., and on behalf of the European Vertebral Osteoporosis Study Group (EVOS). The epidemiology of vertebral fractures. Bone 14 (1993) 589-597
29. Harvey N., Earl S., and Cooper C. Epidemiology of osteoporotic fractures. In: Favus M. (Ed). Primer on the Metabolic Disease and Disorders of Mineral Metabolism. 6th Edition (2006), American Society for Bone and Mineral research, Washington 244-248
30. Fucik R.F., Kukreja S.C., Hargis G.K., Bowser E.N., Henderson W.J., and Williams G.A. Effect of glucocorticoids on function of the parathyroid glands in man. J Clin Endocrinol Metab 40 (1975) 152-155